GlassScriptPhysician profile
Evilio A Prendes
NPI 1689900334
$1,028.12
in general payments reported to CMS, 2019-2025
9 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.28 · 2023: $444 · 2024: $274 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anika Therapeutics, INC. | $336.71 | 2023 | Revomotion, Integrity, Tactoset |
| Amgen INC. | $312.26 | 2024-2025 | Krystexxa |
| Vertex Pharmaceuticals Incorporated | $121.87 | 2025 | |
| Bioventus LLC | $71.63 | 2022-2024 | Exogen Ultrasound Bone Healing System |
| Horizon Therapeutics Plc | $63.38 | 2023 | Krystexxa |
| Electronic Waveform Lab, INC. | $56.48 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $23.61 | 2023 | Seglentis |
| Endo Pharmaceuticals INC. | $22.18 | 2022 | |
| Integra Lifesciences Corporation | $20.00 | 2023 | Tenoglide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evilio Prendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.